Literature DB >> 7526044

Elevation of circulating monitor peptide/pancreatic secretory trypsin inhibitor-I (PSTI-61) after turpentine-induced inflammation in rats: hepatocytes produce it as an acute phase reactant.

K Uda1, A Murata, J Nishijima, S Doi, N Tomita, M Ogawa, T Mori.   

Abstract

Monitor peptide (MP) is a trypsin-sensitive cholecystokinin (CCK)-releasing peptide purified from rat pancreatic juice on the basis of its stimulatory activity toward pancreatic enzyme secretion and has been reported to exhibit cell growth-stimulating activity. Pancreatic secretory trypsin inhibitor (PSTI) prevents premature activation of trypsinogen in the pancreatic duct. There are two PSTIs (PSTI-61 and -56) purified from rat pancreatic juice on the basis of trypsin inhibitory activity as reported previously. Fushiki et al. (1989, FASEB J. 3, 121) showed that MP is structurally the same peptide as PSTI-61. We measured the serial changes of circulating MP/PSTI-61 in rat and those in the level of PSTI-61 mRNA in the rat liver to investigate another novel role of this peptide in the turpentine-induced acute inflammation model. The elevation of serum MP/PSTI-61 as well as the alpha 2-globulin fraction, which is known to include several acute phase reactants such as alpha 2-macroglobulin and haptoglobin, was observed after induction of the turpentine inflammation. The serum alpha 2-globulin fraction had increased approximately 3-fold over the initial level at 48 hr after the injection. In contrast, serum MP/PSTI-61 had increased approximately 17-fold over the initial level at 48 hr after the injection. The elevation of circulating MP/PSTI-61 was significantly related with that of the alpha 2-globulin fraction (r = 0.91, P < 0.01). Immunoreactive MP/PSTI-61 was detected in the liver after induction of the inflammation (152.5 +/- 16.5 ng/g wet weight), but in the normal rat liver there was no immunoreactive MP/PSTI-61.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7526044     DOI: 10.1006/jsre.1994.1183

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  4 in total

1.  Hepatitis B and hepatitis C virus replication upregulates serine protease inhibitor Kazal, resulting in cellular resistance to serine protease-dependent apoptosis.

Authors:  Jason Lamontagne; Mark Pinkerton; Timothy M Block; Xuanyong Lu
Journal:  J Virol       Date:  2009-10-28       Impact factor: 5.103

2.  Pancreatic secretory trypsin inhibitor: More than a trypsin inhibitor.

Authors:  Gai-Ping Wang; Cun-Shuan Xu
Journal:  World J Gastrointest Pathophysiol       Date:  2010-06-15

3.  Role of the inflammatory protein serine protease inhibitor Kazal in preventing cytolytic granule granzyme A-mediated apoptosis.

Authors:  Felix Lu; Jason Lamontagne; Angela Sun; Mark Pinkerton; Timothy Block; Xuanyong Lu
Journal:  Immunology       Date:  2011-12       Impact factor: 7.397

4.  Protection of hepatocytes from cytotoxic T cell mediated killing by interferon-alpha.

Authors:  Christian B Willberg; Scott M Ward; Reginald F Clayton; Nikolai V Naoumov; Christopher McCormick; Sandra Proto; Mark Harris; Arvind H Patel; Paul Klenerman
Journal:  PLoS One       Date:  2007-08-29       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.